These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25623548)

  • 41. Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes.
    Matthews DR; Tsapas A
    Diab Vasc Dis Res; 2008 Sep; 5(3):216-8. PubMed ID: 18777497
    [No Abstract]   [Full Text] [Related]  

  • 42. Diabetes. Paradoxical effects of tightly controlled blood sugar.
    Taubes G
    Science; 2008 Oct; 322(5900):365-7. PubMed ID: 18927369
    [No Abstract]   [Full Text] [Related]  

  • 43. Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus.
    O'Keefe JH; Abuannadi M; Lavie CJ; Bell DS
    Mayo Clin Proc; 2011 Feb; 86(2):128-38. PubMed ID: 21270290
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Replacing Insulin Glargine with Neutral Protamine Hagedorn (NPH) Insulin in a Subpopulation of Study Subjects in the Action to Control Cardiovascular Risk in Diabetes (ACCORD): Effects on Blood Glucose Levels, Hypoglycemia and Patient Satisfaction.
    Berard L; Cameron B; Woo V; Stewart J
    Can J Diabetes; 2015 Aug; 39(4):296-301. PubMed ID: 25819531
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
    Maiorino MI; Longo M; Scappaticcio L; Bellastella G; Chiodini P; Esposito K; Giugliano D
    Cardiovasc Diabetol; 2021 Oct; 20(1):210. PubMed ID: 34663316
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intensified glucose control in type 2 diabetes--whose agenda?
    Yudkin JS; Richter B; Gale EA
    Lancet; 2011 Apr; 377(9773):1220-2. PubMed ID: 21093903
    [No Abstract]   [Full Text] [Related]  

  • 48. Understanding the cardiovascular risk with non-insulin antidiabetic drugs.
    Athyros VG; Imprialos K; Stavropoulos K; Sahinidis A; Doumas M
    Expert Opin Drug Saf; 2019 Mar; 18(3):241-251. PubMed ID: 30810055
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aggressive glycemic control might not be best choice for all diabetic patients.
    Mitka M
    JAMA; 2010 Mar; 303(12):1137-8. PubMed ID: 20332394
    [No Abstract]   [Full Text] [Related]  

  • 50. Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables: overview, meta-analysis of randomized trials.
    Thomopoulos C; Bazoukis G; Ilias I; Tsioufis C; Makris T
    J Hypertens; 2019 Oct; 37(10):1939-1949. PubMed ID: 31157748
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decrease mortality in type II diabetes mellitus: glycemic and renal function control.
    Borghi C; Ventura F
    J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e13-e15. PubMed ID: 29538138
    [No Abstract]   [Full Text] [Related]  

  • 52. The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes.
    Paty BW
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S155-9. PubMed ID: 26654859
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of glycemic control and variability in patients with type 2 and posttransplantation diabetes mellitus.
    Werzowa J; Pacini G; Hecking M; Fidler C; Haidinger M; Brath H; Thomas A; Säemann MD; Tura A
    J Diabetes Complications; 2015; 29(8):1211-6. PubMed ID: 26264400
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Questions for practicing internists].
    Zinnenlauf S
    Praxis (Bern 1994); 2008 Aug; 97(17):945-6. PubMed ID: 18777778
    [No Abstract]   [Full Text] [Related]  

  • 55. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
    Tian J; Ohkuma T; Cooper M; Harrap S; Mancia G; Poulter N; Wang JG; Zoungas S; Woodward M; Chalmers J
    Diabetes Care; 2020 Jun; 43(6):1293-1299. PubMed ID: 32193249
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis.
    Davidson JA; Liebl A; Christiansen JS; Fulcher G; Ligthelm RJ; Brown P; Gylvin T; Kawamori R
    Clin Ther; 2009 Aug; 31(8):1641-51. PubMed ID: 19808125
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A New Algorithm Dedicated to Blood Glucose Monitoring in Insulin-Treated Elderly Dependent People With Diabetes.
    Grino M; Loundou A; Boucekine M; Alitta Q; Oliver C
    J Diabetes Sci Technol; 2019 Mar; 13(2):410-412. PubMed ID: 30537870
    [No Abstract]   [Full Text] [Related]  

  • 58. Cardiovascular disease and type 2 diabetes mellitus: regulating glucose and regulating drugs.
    Gore MO; McGuire DK
    Curr Cardiol Rep; 2009 Jul; 11(4):258-63. PubMed ID: 19563725
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.
    Zinman B; Inzucchi SE; Wanner C; Hehnke U; George JT; Johansen OE; Fitchett D;
    Diabetologia; 2018 Jul; 61(7):1522-1527. PubMed ID: 29713728
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials.
    Ismail-Beigi F; Moghissi E; Tiktin M; Hirsch IB; Inzucchi SE; Genuth S
    Ann Intern Med; 2011 Apr; 154(8):554-9. PubMed ID: 21502652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.